Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis
Public ClinicalTrials.gov record NCT04709575. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy of Anti-Bet v 1 Monoclonal Antibodies to Reduce Symptoms of Seasonal Allergic Rhinitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective is to assess the reduction of allergic symptoms as measured by combined symptom and medication score (CSMS) during birch pollen season after a single dose of REGN5713-5714-5715 versus placebo.
Study identification
- NCT ID
- NCT04709575
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 353 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 14, 2021 (Actual)
- Primary completion
- Aug 24, 2021 (Actual)
- Completion
- Aug 24, 2021 (Actual)
- Last update posted
- Oct 27, 2022
2021
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Regeneron Study Site | Bangor | Maine | 04401 | — |
| Regeneron Study Site | Baltimore | Maryland | 21224 | — |
| Regeneron Study Site | Plymouth | Minnesota | 55441 | — |
| Regeneron Study Site | Columbia | Missouri | 65212 | — |
| Regeneron Study Site | St Louis | Missouri | 63141 | — |
| Regeneron Study Site | Missoula | Montana | 59808 | — |
| Regeneron Study Site | Verona | New Jersey | 07044 | — |
| Regeneron Study Site | Great Neck | New York | 11021 | — |
| Regeneron Study Site | Cincinnati | Ohio | 45231 | — |
| Regeneron Study Site | Toledo | Ohio | 43617 | — |
| Regeneron Study Site | Portland | Oregon | 97202 | — |
| Regeneron Study Site | Pittsburgh | Pennsylvania | 15241 | — |
| Regeneron Study Site | Lincoln | Rhode Island | 02865 | — |
| Regeneron Study Site | Greenfield | Wisconsin | 53228 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04709575, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 27, 2022 · Synced Oct 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04709575 live on ClinicalTrials.gov.